Lupin Ltd Reports Q1 FY2026 Results: Sales Up 11.8%, Net Debt at INR -12,386 Mn

Pharma major Lupin Limited reported its financial performance for the quarter ending June 30, 2025. The company's sales stood at INR 61,638 Mn, up by 11.8% YoY. EBITDA was INR 18,063 Mn, with a margin of 29.3%. The company's net debt stands at INR -12,386 Mn as of June 30, 2025. Lupin received 2 ANDA approvals from the U.S. FDA and launched 3 products in the U.S. market, maintaining its position as the 3rd largest pharmaceutical player in the U.S. generic market and U.S. total market by prescriptions.